Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CLL update 2022: A continuing evolution in care
Neil E. Kay, Paul J. Hampel, Daniel L. Van Dyke, et al.
Blood Reviews (2022) Vol. 54, pp. 100930-100930
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI
Lindsey E. Roeker, John M. Burke, Joanna Rhodes, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 799-799
Open Access
Extracellular Vesicles in Hematological Malignancies
Samir Zuberi, Jihane Khalife
IntechOpen eBooks (2025)
Closed Access
Defining precancer: a grand challenge for the cancer community
Jessica M. Faupel‐Badger, Indu Kohaar, Manisha Bahl, et al.
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 4
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Michele Stanchina, Skye Montoya, Alexey V. Danilov, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 12, pp. 867-887
Closed Access | Times Cited: 4
Chronic Lymphocytic Leukemia
Min Shi, Dragan Jevremović, Curtis A. Hanson, et al.
(2024), pp. 1193-1205
Closed Access | Times Cited: 4
Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment
David Van Morckhoven, Nathan Dubois, Dominique Bron, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia
Sylwia Chocholska, Michał Zarobkiewicz, Agata Szymańska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1705-1705
Open Access | Times Cited: 9
A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL)
Matthew Karr, Lindsey E. Roeker
Cancers (2023) Vol. 15, Iss. 4, pp. 1018-1018
Open Access | Times Cited: 9
How I Manage Chronic Lymphocytic Leukemia
Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, et al.
Hematology Reports (2023) Vol. 15, Iss. 3, pp. 454-464
Open Access | Times Cited: 7
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
Yuqin Song, Shang‐Ju Wu, Zhi-Xiang Shen, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 6
An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies
Sujoy Khan, David Allsup, Stefano Molica
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Sequencing and combination of current small‐molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?
Clement Chung, Godsfavour Umoru, Karen Abboud, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 1, pp. 15-28
Open Access | Times Cited: 5
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Mariana Tannoury, Delphine Garnier, Santos A. Susín, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6026-6026
Open Access | Times Cited: 8
Topological Structures in the Space of Treatment-Naïve Patients With Chronic Lymphocytic Leukemia
Reginald L. McGee, Jake Reed, Caitlin E. Coombes, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
Nilanjan Ghosh, Beenish S. Manzoor, Bita Fakhri, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Efficacy and challenges involving combination therapies in CLL
Majed A Alanazi, Faith Kwa, Musab M. A. Omar, et al.
Drug Discovery Today (2024), pp. 104243-104243
Open Access | Times Cited: 1
Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy
Qi Gao, Xueyan Chen, Sindhu Cherian, et al.
Cytometry Part B Clinical Cytometry (2022) Vol. 104, Iss. 3, pp. 224-242
Closed Access | Times Cited: 7
Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies
Alessandro Allegra, Nicola Cicero, Giuseppe Mirabile, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4182-4182
Open Access | Times Cited: 6
Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?
Justyna Woś, Agata Szymańska, Natalia Lehman, et al.
Cells (2023) Vol. 13, Iss. 1, pp. 30-30
Open Access | Times Cited: 3
The Five “Ws” of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When
Isabel González-Gascón-y-Marín, Mónica Ballesteros-Andrés, Sara Martínez-Flores, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4391-4391
Open Access | Times Cited: 3
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
Jung‐Sun Kim, Tae Min Kim, Myoung Joo Kang, et al.
The Korean Journal of Internal Medicine (2023) Vol. 38, Iss. 5, pp. 747-757
Open Access | Times Cited: 2
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era
María Del Mar Sánchez Suárez, Alicia Martín Roldán, Carolina Alarcón-Payer, et al.
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 55-55
Open Access | Times Cited: 2
Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia
Stefano Molica, David Allsup
The Lancet Oncology (2022) Vol. 23, Iss. 6, pp. 699-701
Open Access | Times Cited: 4
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group
Doreen G. Te Raa, Lina van der Straten, Michel van Gelder, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 10, pp. 2276-2289
Open Access | Times Cited: 3
Hematologists’ perspective on Advance Directives, a French national prospective cross-sectional survey – the ADORE-H Study
Kevin Serey, Amélie Cambriel, Adrien Pollina-Bachellerie, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top